Alpha Cognition

NAQ:ACOG · CA02074J5017

BiotechnologySmall

360

Value42

Profit price83

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price53

Price/Sales85

EV / Gross Profit39

Price/Book36

Quality48

Returns on capital65

Return on Capital56

Cash Return on Capital72

Return on Equity67

Profit margins30

EBIT Margin1

Gross Profitability59

Cash backing42

Accruals30

Owner Earnings Margin54

Growth45

Sales growth64

Profit growth76

Reinvestment41

Price momentum12

Safety29

Debt load68

Debt serviceability49

Refinancing96

Debt Payback1

Liquidity40

Sentiment56

Analyst ratings41

Expectations trend74

Opinion Changes98

Price Target Upside49

Market mood74

Value Creation8/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Alpha Cognition clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryCanada

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQCM

Employees75

Websitealphacognition.com

ISINCA02074J5017

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

NeurologyChronic DiseasesNeuroscienceCentral Nervous SystemHealth CarePharmaceutical

Description

Alpha Cognition Inc. operates as a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease (Alzheimer’s disease or AD), for which there are limited or no treatme…

Analysis

Middle-of-the-road

Alpha Cognition Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 8/20 on our value-creation score: creating some value.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Alpha Cognition with its peers

Anavex Life Sciences

NSQ:AVXL

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Actuate Therapeutics

NMQ:ACTU

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Ionis Pharmaceuticals

NSQ:IONS

CountryUSA

IndustryBiotechnology

SizeLarge

Full Stock Analysis →

Xoma Royalty

NMQ:XOMA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Biogen Idec

NSQ:BIIB

CountryUSA

IndustryBiotechnology

SizeX-Large

Full Stock Analysis →

PTC Therapeutics

NSQ:PTCT

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →